[
  {
    "ts": null,
    "headline": "Will BMY's Oncology Collaborations Drive Its Next Growth Phase?",
    "summary": "BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.",
    "url": "https://finnhub.io/api/news?id=6d3235feb7809fc118260c3964811cf411a3585c4a22acc128c5826ccb345911",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769780940,
      "headline": "Will BMY's Oncology Collaborations Drive Its Next Growth Phase?",
      "id": 138306066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.",
      "url": "https://finnhub.io/api/news?id=6d3235feb7809fc118260c3964811cf411a3585c4a22acc128c5826ccb345911"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year",
    "summary": "All three can provide you with solid, consistent income.",
    "url": "https://finnhub.io/api/news?id=50c5240230cbb28fe77da703a80528db5975c8c2cb5b075bf63d4c67f2b1d7d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769775600,
      "headline": "3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year",
      "id": 138305409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "All three can provide you with solid, consistent income.",
      "url": "https://finnhub.io/api/news?id=50c5240230cbb28fe77da703a80528db5975c8c2cb5b075bf63d4c67f2b1d7d6"
    }
  },
  {
    "ts": null,
    "headline": "How Big Pharma is navigating a $300 billion patent cliff",
    "summary": "Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.",
    "url": "https://finnhub.io/api/news?id=7d91a831517f4f71b90aac9882298a5796b320a690d2e8febe8a55ec5f02581d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769760000,
      "headline": "How Big Pharma is navigating a $300 billion patent cliff",
      "id": 138305298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Drugmakers like J&J, Merck and AbbVie are making gains by not relying on one single strategy to shore up losses.",
      "url": "https://finnhub.io/api/news?id=7d91a831517f4f71b90aac9882298a5796b320a690d2e8febe8a55ec5f02581d"
    }
  },
  {
    "ts": null,
    "headline": "Microsoft’s AI Growth Story Tests Investor Patience On Heavy Spending",
    "summary": "Microsoft (NasdaqGS:MSFT) reported second quarter results with record cloud and AI revenues and the launch of its Maia 200 AI chip. The company highlighted strong AI related customer commitments, including from OpenAI, contributing to a growing business backlog. Despite beating earnings expectations, Microsoft shares saw their steepest single day decline since 2020 as investors focused on heavy AI infrastructure spending and slower Azure growth. Microsoft announced new AI partnerships,...",
    "url": "https://finnhub.io/api/news?id=5657a4e0c58b802d8f0d4bd46e16930f296e7c1e4336403fbda5abc76eb28367",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769756873,
      "headline": "Microsoft’s AI Growth Story Tests Investor Patience On Heavy Spending",
      "id": 138303528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Microsoft (NasdaqGS:MSFT) reported second quarter results with record cloud and AI revenues and the launch of its Maia 200 AI chip. The company highlighted strong AI related customer commitments, including from OpenAI, contributing to a growing business backlog. Despite beating earnings expectations, Microsoft shares saw their steepest single day decline since 2020 as investors focused on heavy AI infrastructure spending and slower Azure growth. Microsoft announced new AI partnerships,...",
      "url": "https://finnhub.io/api/news?id=5657a4e0c58b802d8f0d4bd46e16930f296e7c1e4336403fbda5abc76eb28367"
    }
  },
  {
    "ts": null,
    "headline": "Piramal Pharma Ltd (BOM:543635) Q3 2026 Earnings Call Highlights: Navigating Challenges and ...",
    "summary": "Piramal Pharma Ltd (BOM:543635) shows resilience with strategic acquisitions and growth in consumer healthcare amidst revenue challenges.",
    "url": "https://finnhub.io/api/news?id=3f79afe1333b26e2bed639a591ddc62bf8f0420e2729af1279a6858b78c97373",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769742146,
      "headline": "Piramal Pharma Ltd (BOM:543635) Q3 2026 Earnings Call Highlights: Navigating Challenges and ...",
      "id": 138302569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Piramal Pharma Ltd (BOM:543635) shows resilience with strategic acquisitions and growth in consumer healthcare amidst revenue challenges.",
      "url": "https://finnhub.io/api/news?id=3f79afe1333b26e2bed639a591ddc62bf8f0420e2729af1279a6858b78c97373"
    }
  }
]